CTOs on the Move

Lyndra

www.lyndra.com

 
Lyndra Therapeutics is pioneering the first-ever oral, ultra-long-acting, sustained release therapies, which have the potential to fundamentally change the way people take medicine by enabling patients to take a pill once a week rather than daily. The Company`s breakthrough Extended-Release Oral Capsule is designed to provide consistent drug levels for an entire week or as long as a month, from one, normal-sized capsule – something no oral therapy has ever achieved before. Lyndra`s robust pipeline is made up of therapies with established and well-known safety profiles across a number of disease areas in which non-adherence is known to be a ...
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million
  • www.lyndra.com
  • 65 Grove Street Suite 301
    Watertown, MA USA 02472
  • Phone: 857.201.5314

Executives

Name Title Contact Details
Jacqueline Fernandes
 Vice President of Data Compliance and Information Technology Profile
Kyle Haraldsen
 Chief Technology Officer Profile
Orn Almarsson
 Chief Technology Officer Profile

Funding

Lyndra raised $23M on 04/13/2017
Lyndra raised $55M on 01/29/2019
Lyndra raised $13M on 07/30/2019

Similar Companies

Jasper Clinical Research and Development

Jasper Clinical Research and Development, Inc. is a Kalamazoo, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Meso Scale Discovery

Meso Scale Discovery is a Gaithersburg, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

FluroTech

FluroTech is a technology and marketing company whose core business is focused on the commercialization of new technologies in the cannabis industry. FluroTech`s proprietary spectroscopy-based technology allows for the testing and identification of organic and inorganic compounds contained within biological samples derived from cannabis plants. Using the technology that was developed at the University of Calgary in conjunction with the University of Alberta, FluroTech has developed a two-part solution comprising an instrument called the CompleTest™ and consumable testing kits.

Sage Therapeutics

Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. Sage`s lead product candidate, ZULRESSO(TM) (brexanolone) injection, has completed Phase 3 clinical development for postpartum depression and a New Drug Application is currently under review with the U.S. Food and Drug Administration. Sage is developing a portfolio of novel product candidates targeting critical CNS receptor systems, including SAGE-217, which is in Phase 3 development in major depressive disorder and postpartum depression.

Vysis

Vysis, Inc. is a Downers Grove, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.